International multicenter validation of GES score for HCC risk stratification in chronic hepatitis C patients

Gamal Shiha (1) , Reham Soliman (1) , Nabiel Mikhail (1) , Fabrice Carrat (2, 3) , Jessica Azzi (2) , Ganne-Carrié Nathalie (4, 5) , Hidenori Toyoda , Haruki Uojima (6) , Akito Nozaki (7) , Koichi Takaguchi (8) , Atsushi Hiraoka (9) , Masanori Atsukawa (10) , Hiroshi Abe , Kentaro Matsuura (11) , Shigeru Mikami , Tsunamasa Watanabe (12) , Kunihiko Tsuji , Toru Ishikawa , Vithika Suri (13) , Anu Osinusi (13) , Liyun Ni (13) , Jun Zou (13) , Shiv Kumar Sarin (14) , Manoj Kumar (14) , Prasun Kumar Jalal (15) , Mahmoud Hashim (15) , Manal Hassan (15) , Sonia Alonso Lopez (16, 17) , Rafael Bañares (17, 16) , Adriana Ahumada (16) , Nasser Hamed Mousa (1) , Mohammed Eslam (18, 19) , Imam Waked (1)

1 Mansoura University [Egypt]
2 iPLESP - Institut Pierre Louis d'Epidémiologie et de Santé Publique
3 CHU Saint-Antoine [AP-HP]
4 CRC (UMR_S_1138 / U1138) - Centre de Recherche des Cordeliers
5 Hôpitaux Paris Seine-Saint-Denis [Bobigny]
6 Kitasato University
7 Yokohama National University
8 Kagawa University [Japan]
9 Ehime University [Matsuyama, Japon]
10 Nippon Medical School [Tokyo, Japon]
11 Nagoya City University [Nagoya, Japan]
12 St. Marianna University School of Medicine [Kanagawa, Japan]
13 Gilead Sciences, Inc. [Foster City, CA, USA]
14 Institute of Liver and Biliary Sciences [New Delhi]
15 BCM - Baylor College of Medicine
16 Hospital General Universitario "Gregorio Marañón" [Madrid]
17 CIBERehd - Centro de Investigación Biomédica en Red en el Área temática de Enfermedades Hepáticas y Digestivas
18 Westmead Hospital [Sydney]
19 The University of Sydney

We have recently demonstrated the ability of a simple predictive model (GES) score to determine the risk of hepatocellular carcinoma (HCC) after using direct-acting antivirals. However, our results were restricted to Egyptian patients with hepatitis C virus (HCV) genotype 4. Therefore, we studied a large, independent cohort of multiethnic populations through our international collaborative activity. Depending on their GES scores, patients are stratified into low risk (≤ 6/12.5), intermediate risk (> 6-7.5/12.5), and high risk (> 7.5/12.5) for HCC. A total of 12,038 patients with chronic HCV were analyzed in this study, of whom 11,202 were recruited from 54 centers in France, Japan, India, the U.S., and Spain, and the remaining 836 were selected from the Gilead-sponsored randomized controlled trial conducted across the U.S., Europe, Canada, and Australia. Descriptive statistics and log-rank tests. The performance of the GES score was evaluated using Harrell's C-index (HCI). The GES score proved successful at stratifying all patients into 3 risk groups, namely low-risk, intermediate-risk, and high-risk. It also displayed significant predictive value for HCC development in all participants (p < .0001), with HCI ranging from 0.55 to 0.76 among all cohorts after adjusting for HCV genotypes and patient ethnicities. The GES score can be used to stratify HCV patients into 3 categories of risk for HCC, namely low-risk, intermediate-risk, and high-risk, irrespective of their ethnicities or HCV genotypes. This international multicenter validation may allow the use of GES score in individualized HCC risk-based surveillance programs.

Mots clés: AFP; CHC; HCC risk scores

Domaines: Santé publique et épidémiologie

Gamal Shiha, Reham Soliman, Nabiel Mikhail, Fabrice Carrat, Jessica Azzi, et al.. International multicenter validation of GES score for HCC risk stratification in chronic hepatitis C patients. Journal of Viral Hepatitis, 2022, 29 (9), pp.807 - 816. ⟨10.1111/jvh.13717⟩. ⟨hal-03785890⟩